A carregar...
1ISG-007 Biosimilar of infliximab: does the penetration rate meet expectations? appraisal in a central purchasing office
BACKGROUND: Prescription of biosimilars on a large scale is an important lever to decrease hospital expenses. As a result, 40 M€ of savings are expected in the healthcare bill by the promotion of biosimilar use in 2018. In 2015, one wholesaler (WS) listed one of the two biosimilars of infliximab. PU...
Na minha lista:
| Publicado no: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Group
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535251/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|